A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home 2012 October
formats

RF Programming Hack Demonstrates Potentially Fatal ICD Exploit

I received today a link to a very interesting article which plays on the fears of the public, and which I am sure will result in tough new regulations to our industry. The article discusses how IOActive researcher Barnaby Jack reverse-engineered a “pacemaker transmitter” (probably a programmer or a MICS module) to command ICDs within a 30

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on RF Programming Hack Demonstrates Potentially Fatal ICD Exploit  comments 
formats

Boston Scientific’s Q3 2012 AIMD Results: CRM Dropped 6%, Neuromodulation Up 5%

Today Boston Scientific reported its results for Q3 2012.  For its AIMD divisions: Cardiac Rhythm Management sales dropped from $503M in Q3 of 2011 to $462M for this year (-8%), a 6% decrease on constant-currency basis. Neuromodulation sales grew by 5% from $84M to $88M.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific’s Q3 2012 AIMD Results: CRM Dropped 6%, Neuromodulation Up 5%  comments 
formats

Biotronik Launches Implantable BioMonitor for Monitoring Arrhythmias

Biotronik announced the European market release of BioMonitor®, an implantable cardiac device designed for the highly accurate and reliable monitoring and management of patients with atrial fibrillation (AF) or unexplained syncope. According to Biotronik’s press release: “BioMonitor® is a subcutaneous implantable leadless cardiac monitor for the long-term continuous remote monitoring of patients with arrhythmias such as

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Biotronik Launches Implantable BioMonitor for Monitoring Arrhythmias  comments 
formats

St. Jude’s Q3 2012 AIMD Results: CRM Maintains Downward Trend, Neuromodulation Steady

St. Jude announced today its third quarter 2012 results.  From the press release: “Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $691 million for the third quarter of 2012, an 8 percent decrease compared with the third quarter of 2011. Total CRM sales for the third quarter decreased 4 percent

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude’s Q3 2012 AIMD Results: CRM Maintains Downward Trend, Neuromodulation Steady  comments 
formats

Transient Electronics Opens Path Toward Absorbable, Transient AIMDs

A collaboration of Tufts Univeristy, University of Illinois and the Defense Advanced Research Projects Agency (DARPA) resulted in the development of electronic devices that dissolve in water or biological fluids dissolves and break down in traces of silicon and magnesium. Because of the small amount, these components can be harmlessly assimilated by biosystems like the human body, potentially

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Transient Electronics Opens Path Toward Absorbable, Transient AIMDs  comments